|  |
| --- |
| Losartan |
| Preparations listed in the Drug tariff**Hover the mouse over the £ sign for DT prices** | [**Part VIIIA (hover the mouse here for more info):**](#_References) | **DT price** |
| Losartan 12.5mg, 25mg,50mg, 100mg tablets | [**£**](#_Losartan) |
| Losartan/hydrochlorothiazide 50mg/12.5mg, 100mg/12.5mg, 100mg/25mg, tablets | [**£**](#_Losartan) |
| [**Part VIIIB (hover the mouse here for more info):**](#_References) | **DT price** |
| 50mg/5ml oral suspension | [**£**](#_Losartan) |
| Administration in swallowing difficulties |
| Crush tablets and mix with water immediately prior to administration (unlicensed)1 If route of administration is likely to be long-term, consider changing to irbesartan due to lack of data and poor dispersion characteristics1 |
| Administration in enteral feeding tube |
| Crush the tablet (unlicensed) in a mortar and mix in a few ml of water to make a paste. Add up to 15ml water and mix thoroughly. Draw into syringe and flush down the feeding tube. Add 15ml to the mortar and stir to collect any remaining drug. Draw this fluid into a syringe and flush down the feeding tube1.If route of administration is likely to be long-term, consider changing to irbesartan due to lack of data and poor dispersion characteristics1 |
| Comments |
| No additional information was obtained from MSD for Cozaar or Cozaar-Comp (losartan/hydrochlorothiazide) 2,3. Cozaar oral suspension was discontinued July 2019. |
| References1. White R and Bradnam V. Handbook of Drug Administration via enteral feeding tubes. 3rd edition, 2015. Pharmaceutical Press
2. Email correspondence on file: Cozaar (email reference: gb19-04000). Merck Sharp & Dohme Medicines information. Received 26 April 2019
3. Email correspondence on file: Cozaar-Comp (email reference: gb19-04000). Merck Sharp & Dohme Medicines information. Received 25 April 2019
4. Drug Tariff May 2019 <https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff> date accessed 23 May 2019
 |
| **Please note: full instructions should be provided to the person administering the medicine. This is guidance only and should not determine individualised care.** |
| Author: Vicki Kong, QIPP Programme Pharmacist, BHR CCGsApproved by BHR CCGs Area Prescribing sub-Committees: July 2019 |
| Review date: July 2021 | Version: 1 |